Cargando…
Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial
PURPOSE: To evaluate oral setipiprant versus placebo for scalp hair growth in men with androgenetic alopecia (AGA). PATIENTS AND METHODS: Males aged 18 to 49 years with AGA were enrolled in a double-blind, multicenter, 32-week, phase 2a trial; randomized to twice-daily (BID) 1000-mg (2×500 mg for a...
Autores principales: | DuBois, Janet, Bruce, Suzanne, Stewart, Daniel, Kempers, Steven, Harutunian, Christy, Boodhoo, Terry, Weitzenfeld, Amy, Chang-Lin, Joan-En |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526366/ https://www.ncbi.nlm.nih.gov/pubmed/34703265 http://dx.doi.org/10.2147/CCID.S319676 |
Ejemplares similares
-
Androgenetic alopecia: An update
por: Ntshingila, Sincengile, et al.
Publicado: (2023) -
Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies
por: Ratner, Paul, et al.
Publicado: (2017) -
Characteristics of Androgenetic Alopecia in Asian
por: Lee, Won-Soo, et al.
Publicado: (2012) -
Oxidative stress in androgenetic alopecia
por: Prie, BE, et al.
Publicado: (2016) -
Trichoscopic Findings in Androgenetic Alopecia
por: Kasumagic-Halilovic, Emina
Publicado: (2021)